29 completed, 15 active not recruiting, 15 recruiting, 14 terminated. 87 Phase 2, 25 Phase 1, 1 Phase 3.
Follow Clear Cell Renal Cell Carcinoma: new trials by email Literature Review of Clear Cell Renal Cell Carcinoma trials Research Report on Clear Cell Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery Biospecimen Collection, Clostridium butyricum CBM588 Strain, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 62 | 2026-07-08 | 2026-10-19 |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma TQB2450 + Anlotinib - Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | RenJi Hospital | 33 | 2026-05-31 | 2026-05-22 |
| Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC XL092, Nivolumab - Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Recruiting | Karie Runcie | 70 | 2026-03-13 | 2026-09-22 |
| An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma SLC-3010 + Axitinib, Axitinib - Clear Cell Renal Cell Carcinoma, Neoplasms | Phase 2 | Recruiting | Yonsei University | 78 | 2026-03-01 | 2026-03-13 |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer PF-08634404, Ipilimumab, Axitinib - Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | Pfizer | 224 | 2026-02-10 | 2026-10-08 |
| Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution - Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | University of Oklahoma | 72 | 2026-01-15 | 2026-03-02 |
| Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE) Pembrolizumab, Belzutifan - Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 10 | 2025-12-19 | 2026-08-20 |
| Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC QL1706 Combined With Lenvatinib - Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 25 | 2025-11-21 | 2026-02-05 |
| Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC) Belzutifan, Active Surveillance - Active Surveillance, Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 78 | 2025-11-17 | 2026-05-22 |
| Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC piflufolastat F 18 - Clear Cell Renal Cell Carcinoma | Phase 2 / Phase 3 | Withdrawn | Lantheus Medical Imaging | 2025-11-01 | 2025-12-10 | |
| 68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses 68Ga-NYM096 PET/CT - Clear Cell Renal Cell Carcinoma | Phase 2 | Enrolling by invitation | Peking Union Medical College Hospital | 100 | 2025-07-01 | 2025-08-08 |
| Immune PET and Proteomics for the Assessment of Response to Spatially Fractionated or Palliative Radiotherapy With or Without Immunotherapy Baseline 89-Zr Pembrolizumab Immuno PET-CT, Proteomic assay, Follow-up 89-Zr Pembrolizumab Immuno PET-CT - Triple Negative Breast Cancer, Uterine Cervical Cancer | Phase 2 | Not yet recruiting | Maria Sklodowska-Curie National Research Institute of Oncology | 60 | 2025-06-01 | 2025-05-16 |
| Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma Cadonilimab,Lenvatinib - Renal Cell Carcinoma (Kidney Cancer), Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 54 | 2025-04-01 | 2026-11-02 |
| Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC Pembrolizumab, Axitinib - Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma | Phase 2 | Suspended | H. Lee Moffitt Cancer Center and Research Institute | 75 | 2025-02-25 | 2026-03-06 |
| An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer Biospecimen Collection, Bone Scan, Computed Tomography - Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 91 | 2024-08-06 | 2026-06-15 |
| Combination of Toripalimab and JS004 Therapy for ccRCC JS004, Toripalimab, Axitinib - Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Fudan University | 80 | 2024-06-01 | 2024-11-15 |
| 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC. 68Ga-NY104 PET/CT, 18F-FDG PET/CT, Radiation Therapy - Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Peking Union Medical College Hospital | 40 | 2024-03-27 | 2024-09-27 |
| Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC Cadonilimab Combined With Lenvatinib - Clear Cell Renal Cell Carcinoma | Phase 2 | Completed | Sun Yat-sen University | 39 | 2023-09-01 | 2026-04-21 |
Showing 20 of 87. Sign in to see all of them.
Carcinoma, Renal Cell (87) · Kidney Neoplasms (9) · Neoplasm Metastasis (9) · Clear-cell metastatic renal cell carcinoma (5) · Neoplasms (5) · Carcinoma (4) · Melanoma (4) · Triple Negative Breast Neoplasms (4) · Carcinoma, Ovarian Epithelial (3) · Colorectal Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Uterine Cervical Neoplasms (3) · Anemia, Refractory (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Transitional Cell (2)
Female Urogenital Diseases (87) · Female Urogenital Diseases and Pregnancy Complications (87) · Male Urogenital Diseases (87) · Neoplasms by Histologic Type (87) · Urogenital Diseases (87) · Adenocarcinoma (86) · Neoplasms by Site (86) · Neoplasms, Glandular and Epithelial (86) · Urogenital Neoplasms (86) · Urologic Diseases (86) · Kidney Diseases (85) · Urologic Neoplasms (85) · Carcinoma (83) · Neoplasms (82) · Kidney Neoplasms (78)
Axitinib (13) · Nivolumab (9) · pembrolizumab (8) · Bevacizumab (7) · Sorafenib (7) · cabozantinib (5) · Specimen Handling (4) · Sunitinib (4) · lenvatinib (4) · pazopanib (4) · Disulfides (3) · Immunoglobulin G (3) · Introns (3) · Magnetic Resonance Spectroscopy (3) · Radiotherapy (3)
National Cancer Institute (NCI) (18) · M.D. Anderson Cancer Center (4) · Peking Union Medical College Hospital (4) · Calithera Biosciences, Inc (2) · Case Comprehensive Cancer Center (2) · City of Hope Medical Center (2) · Fred Hutchinson Cancer Center (2) · NiKang Therapeutics, Inc. (2) · RenJi Hospital (2) · Roswell Park Cancer Institute (2) · Sun Yat-sen University (2) · Tianjin Medical University Second Hospital (2) · X4 Pharmaceuticals (2) · 23andMe, Inc. (1) · Academic and Community Cancer Research United (1)
United States (62) · China (13) · Australia (5) · Canada (5) · South Korea (4) · Germany (3) · Spain (3) · France (2) · Italy (2) · New Zealand (2) · Belgium (1) · Brazil (1) · Ireland (1) · Japan (1) · Netherlands (1)
Brian Rini (3) · Eric Jonasch, MD (3) · Brenda Sandmaier (2) · Eric Jonasch (2) · Li Huo, MD (2) · Saby George (2) · Adanma Anji Ayanambakkam Attanathi (1) · Adanma Ayanambakkam, MD (1) · Ajjai Alva, M.D. (1) · Arash Yavari, MBBS (1) · Brian I Rini, MD (1) · Brian Shuch (1)
PMID 32499241, PMID 37146227, PMID 18272024, PMID 25532471, PMID 25900027, PMID 26077237, PMID 28549224, PMID 29550566, PMID 31371341, PMID 31399500, PMID 31654285, PMID 33305087, PMID 33507454, PMID 33604999, PMID 34783716, PMID 35507017, PMID 35576438, PMID 36848607, PMID 38302476, PMID 38396300, PMID 38920407, PMID 39149474, PMID 39462179, PMID 39651931, PMID 40549043, PMID 41654611, PMID 41686845, PMID 42476727, PMID 42507969, PMID 42719952
N01CM62201 (2), N01CM62202 (2), N01CM62209 (2), P01CA018029 (2), P30CA015704 (2), P30CA016672 (2), P30CA033572 (2), U01CA070095 (2), U10CA180821 (2), UM1CA186689 (2), 2016 (1), 2023 (1), 2025 (1), N01CM00032 (1), N01CM00038 (1)